- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| METIS TECHBIO Aktie jetzt für 0€ handeln | |||||
| 04.08. | METIS TECHBIO-P (07666): (1) APPOINTMENT OF JOINT COMPANY SECRETARY; AND (2) WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES | - | HKEx | ||
| 03.08. | METIS TECHBIO-P AI Formulation Platform Secures Localized Deployment at HENGRUI PHARMA | 3 | AASTOCKS | ||
| 03.08. | METIS TECHBIO-P (07666): VOLUNTARY ANNOUNCEMENT METIS TECHBIO ANNOUNCES COLLABORATION WITH HENGRUI PHARMACEUTICALS ON THE AITEM ARTIFICIAL INTELLIGENCE ... | 2 | HKEx | ||
| 31.07. | METIS TECHBIO-P (07666): (1) RESIGNATION OF CHIEF FINANCIAL OFFICER, BOARD SECRETARY AND JOINT COMPANY SECRETARY AND CHANGE OF PROCESS AGENT; (2) CHANGE ... | 2 | HKEx | ||
| 30.06. | Deerfield's Boulevard Bio pens $1.6B deal for trispecific TCE from China's Metis TechBio | 2 | FierceBiotech | ||
| 30.06. | Metis TechBio seals $1.62b global licensing deal with Boulevard Bio | 1 | China Daily | ||
| 30.06. | METiS TechBio vergibt Lizenz für Wirkstoffkandidaten in 1,6-Milliarden-Dollar-Deal | - | Investing.com Deutsch | ||
| 30.06. | METiS TechBio licenses drug candidate to Boulevard Bio for $1.6B | 3 | Investing.com | ||
| 30.06. | METIS TECHBIO-P (07666): VOLUNTARY ANNOUNCEMENT METIS TECHBIO ANNOUNCES A PRECLINICAL TCE LICENSING COLLABORATION WITH DEERFIELD OF UP TO US$1.6 BILLION | 2 | HKEx | ||
| 22.06. | METIS TECHBIO-P (07666): NOTIFICATION LETTER TO NON-REGISTERED HOLDERS OF AND REQUEST FORM - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS | - | HKEx | ||
| 22.06. | METIS TECHBIO-P (07666): NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS | 1 | HKEx | ||
| 12.06. | METIS TECHBIO-P (07666): CHANGE OF JOINT COMPANY SECRETARY AND AUTHORIZED REPRESENTATIVE AND WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF ... | 1 | HKEx | ||
| 10.06. | METIS TECHBIO-P (07666): NEXT DAY DISCLOSURE RETURN | 3 | HKEx | ||
| 10.06. | METIS TECHBIO-P (07666): ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| 10.06. | METIS TECHBIO-P (07666): AMENDMENTS TO THE ARTICLES OF ASSOCIATION | - | HKEx | ||
| 05.06. | METIS TECHBIO-P (07666): FULL EXERCISE OF THE OVER-ALLOTMENT OPTION, STABILIZING ACTIONS AND END OF STABILIZATION PERIOD | 3 | HKEx | ||
| 26.05. | METIS TECHBIO-P (07666): CLARIFICATION ANNOUNCEMENT | 2 | HKEx | ||
| 18.05. | XFRA NEW INSTRUMENTS AVAILABLE ON 18.05.2026 | 1.018 | Xetra Newsboard | The following instruments on XETRA do have their first trading 18.05.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 18.05.2026
Aktien
1 US29333R1077 Enhanced Group Inc.
2... ► Artikel lesen | |
| 14.05. | Metis TechBio records HK's largest healthcare IPO in '26 | 2 | China Daily | ||
| 12.05. | METIS TECHBIO-P (07666): ANNOUNCEMENT OF ALLOTMENT RESULTS | 1 | HKEx |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEMPUS AI | 47,355 | -0,72 % | Opening Bell: Wall Street auf Erholungskurs; Alphabet, SpaceX, Intel, Tempus AI, NextEra Energy ... | Die US-Börsen wagen am Freitag wohl einen Stabilisierungsversuch nach dem erneuten Rückschlag am Vortag. Besonders galt dies für den Leitindex Dow Jones Industrial, der eine Stunde vor dem Auftakt vom... ► Artikel lesen | |
| MANNKIND | 3,352 | -0,62 % | H.C. Wainwright reiterates Buy rating on MannKind stock at $10 | ||
| NEOVACS | 1,140 | 0,00 % | XFRA NEW INSTRUMENTS AVAILABLE ON 23.06.2026 | The following instruments on XETRA do have their first trading 23.06.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 23.06.2026
Aktien
1 CNE100007CW0 Shenzen Xunce Technology... ► Artikel lesen | |
| SIONNA THERAPEUTICS | 4,500 | 0,00 % | Sionna Therapeutics, Inc.: Sionna Therapeutics Reports Topline Data from Two Development Programs in Cystic Fibrosis and Provides Corporate Update | SION-719 Phase 2a proof-of-concept trial did not achieve key activity endpoint of sweat chloride reduction when added to standard of care; Company is not advancing SION-719 as an add-on to standard... ► Artikel lesen | |
| COGENT BIOSCIENCES | 41,510 | -0,05 % | Cogent Biosciences, Inc. - 10-Q, Quarterly Report | ||
| APOGEE THERAPEUTICS | 134,64 | -0,01 % | Apogee Therapeutics: Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates | AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive... ► Artikel lesen | |
| TANGO THERAPEUTICS | 27,670 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Announces Executive Chair Transition | BOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer... ► Artikel lesen | |
| ABSCI | 9,010 | 0,00 % | Morning Market Movers: Cuprina Holdings, CEA Industries, Absci, The Wendy's Company See Big Swings | MEMPHIS (dpa-AFX) - At 7:10 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| CG ONCOLOGY | 76,59 | +0,04 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| DISC MEDICINE | 78,28 | 0,00 % | Disc Medicine Inc: Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update | Completed Type A meeting with the FDA on bitopertin and aligned that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response; topline data expected in Q4 2026Launched Expanded... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 25,910 | -0,04 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| BICARA THERAPEUTICS | 27,730 | 0,00 % | Bicara Therapeutics Inc.: Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ET | ||
| DYNE THERAPEUTICS | 26,500 | 0,00 % | PetAg expands Tractor Supply distribution of supplements, life-stage nutrition: The company's Dyne Soft Chews and Esbilac ... | ||
| MAZE THERAPEUTICS | 27,280 | 0,00 % | Maze Therapeutics, Inc.: Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights | Positive topline data from Phase 2 HORIZON trial of MZE829 in patients with broad AMKD provide proof-of-concept and support advancement into pivotal trial; additional HORIZON data expected in late... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,890 | +0,13 % | H.C. Wainwright reiterates Neutral stock rating on Summit Therapeutics |
Das Unternehmen METIS TECHBIO CO LTD kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +10,77 % bei einem Aktienkurs von 1,389 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu METIS TECHBIO CO LTD finden Sie auf Wallstreet Online.